Moleculin Biotech Announces Release of Next CEO Corner Segment on MIRACLE Study Progress

Moleculin Biotech has released the next segment of its CEO Corner, focusing on the MIRACLE Study evaluating Annamycin in combination with cytarabine for relapsed or refractory Acute Myeloid Leukemia. The adaptive Phase 3 trial has progressed as planned, with completion of treatment for the first 45 patients expected soon. The study builds on encouraging results from the MB-106 Study, where AnnAraC demonstrated overall survival outcomes exceeding historical benchmarks in this patient population.